Moderna, Inc. (MRNA)今日盘中股价大幅上涨16.56%，引起了市场的广泛关注。
消息面上，公司此前公布的一季度营收达3.89亿美元，远超分析师平均预期的2.28亿美元，主要受益于国际新冠疫苗销量强劲增长，公司同时重申了全年营收同比增长10%的目标。此外，公司在AACR会议上披露的mRNA个性化肿瘤治疗性疫苗EVM16首次人体数据表现积极，展现出良好的安全性与初步疗效。瑞银近期上调公司目标价，进一步提振了市场信心。
综合来看，强劲的财务表现与积极的研发进展共同推动了Moderna股价在今日交易时段内的大幅攀升。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.